{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:50:47Z","timestamp":1788306647139,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000319","name":"Alzheimer's Research Trust","doi-asserted-by":"publisher","award":["20164"],"award-info":[{"award-number":["20164"]}],"id":[{"id":"10.13039\/501100000319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.berh.2017.12.002","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T11:30:01Z","timestamp":1517484601000},"page":"441-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Genetic interferonopathies: An overview"],"prefix":"10.1016","volume":"31","author":[{"given":"Despina","family":"Eleftheriou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5775","key":"10.1016\/j.berh.2017.12.002_bib1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.1125676","article-title":"Type 1 interferons and the virus-host relationship: a lesson in detente","volume":"312","author":"Garc\u00eda-Sastre","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.berh.2017.12.002_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","article-title":"Type I interferonopathies: mendelian type I interferon up-regulation","volume":"32","author":"Crow","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.berh.2017.12.002_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2017.12.002_bib4","series-title":"Seminars in immunopathology","article-title":"Type I interferonopathies\u2013an expanding disease spectrum of immunodysregulation","year":"2015"},{"issue":"1","key":"10.1016\/j.berh.2017.12.002_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12969-016-0094-4","article-title":"Type I interferonopathies in pediatric rheumatology","volume":"14","author":"Volpi","year":"2016","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ijd.12695","article-title":"Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management","volume":"54","author":"McDermott","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.berh.2017.12.002_bib7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3389\/fimmu.2017.00927","article-title":"CANDLE syndrome as a paradigm of proteasome-related autoinflammation","volume":"8","author":"Torrelo","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.berh.2017.12.002_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in PSMB8 cause CANDLE syndrome with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","article-title":"PSMB8 encoding the \u03b25i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome","volume":"87","author":"Agarwal","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1016\/j.berh.2017.12.002_bib10","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1172\/JCI58414","article-title":"A\u00a0mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans","volume":"121","author":"Kitamura","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"36","key":"10.1016\/j.berh.2017.12.002_bib11","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1073\/pnas.1106015108","article-title":"Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome","volume":"108","author":"Arima","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.berh.2017.12.002_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/DAD.0000000000000340","article-title":"The histological and immunohistochemical features of the skin lesions in CANDLE syndrome","volume":"37","author":"Torrelo","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.berh.2017.12.002_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2009.04.046","article-title":"Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome","volume":"62","author":"Torrelo","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno-and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress","volume":"142","author":"Seifert","year":"2010","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.berh.2017.12.002_bib16","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","article-title":"Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production","volume":"125","author":"Brehm","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2017.12.002_bib18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/art.38998","article-title":"Stimulator of interferon genes\u2013associated vasculitis of infancy","volume":"67","author":"Omoyinmi","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2017.12.002_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201510-2102LE","article-title":"Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy","volume":"194","author":"Clarke","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.berh.2017.12.002_bib20","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1172\/JCI79100","article-title":"Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations","volume":"124","author":"Jeremiah","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.berh.2017.12.002_bib21","unstructured":"http:\/\/fmf.igh.cnrs.fr\/ISSAID\/infevers\/search.php?n=24. In fever website TMEM 173 variants; 2017."},{"issue":"1","key":"10.1016\/j.berh.2017.12.002_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jaad.2015.10.007","article-title":"Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy","volume":"74","author":"Chia","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.berh.2017.12.002_bib23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamadermatol.2015.0251","article-title":"Stimulator of interferon genes\u2013associated vasculopathy with onset in infancy: a mimic of childhood granulomatosis with polyangiitis","volume":"151","author":"Munoz","year":"2015","journal-title":"JAMA dermatol"},{"issue":"10","key":"10.1016\/j.berh.2017.12.002_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","article-title":"Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus","volume":"94","author":"Kim","year":"2016","journal-title":"J\u00a0Mol Med"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib25","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fr\u00e9mond","year":"2016","journal-title":"J\u00a0Allerg Clin Immunol"},{"key":"10.1016\/j.berh.2017.12.002_bib26","series-title":"Journal of clinical immunology","article-title":"Efficacy of the JAK inhibitor ruxolitinib in two patiens with SAVI syndrome","year":"2017"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1469-8749.2008.02062.x","article-title":"Aicardi-Goutieres syndrome: an important Mendelian mimic of congenital infection","volume":"50","author":"Crow","year":"2008","journal-title":"Dev Med Child Neurol"},{"issue":"R2","key":"10.1016\/j.berh.2017.12.002_bib28","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1093\/hmg\/ddp293","article-title":"Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity","volume":"18","author":"Crow","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajmg.a.36887","article-title":"Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1","volume":"167","author":"Crow","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"8","key":"10.1016\/j.berh.2017.12.002_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/ng1845","article-title":"Mutations in the gene encoding the 3\u2032-5\u2032 DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus","volume":"38","author":"Crow","year":"2006","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.berh.2017.12.002_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ng1842","article-title":"Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection","volume":"38","author":"Crow","year":"2006","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib32","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajmg.a.33359","article-title":"Familial Aicardi\u2013Goutieres syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures","volume":"152","author":"Dale","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.berh.2017.12.002_bib33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/humu.22087","article-title":"SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi\u2013gouti\u00e8res syndrome-associated mutations","volume":"33","author":"Goncalves","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.berh.2017.12.002_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jmedgenet-2013-102038","article-title":"A\u00a0type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1","volume":"51","author":"Livingston","year":"2014","journal-title":"J\u00a0Med Genet"},{"issue":"11","key":"10.1016\/j.berh.2017.12.002_bib35","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.2414","article-title":"Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature","volume":"44","author":"Rice","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2017.12.002_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0037-1601449","article-title":"Genetic, phenotypic, and interferon biomarker status in ADAR1-related neurological disease","volume":"48","author":"Rice","year":"2017","journal-title":"Neuropediatrics"},{"issue":"5","key":"10.1016\/j.berh.2017.12.002_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ng.2933","article-title":"Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling","volume":"46","author":"Rice","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.berh.2017.12.002_bib38","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.4049\/jimmunol.1400737","article-title":"TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner","volume":"192","author":"Ablasser","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.berh.2017.12.002_bib39","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4049\/jimmunol.1500969","article-title":"Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi\u2013Gouti\u00e8res syndrome","volume":"195","author":"Gray","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.berh.2017.12.002_bib40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1084\/jem.20120876","article-title":"Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity","volume":"209","author":"Hiller","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.berh.2017.12.002_bib41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2012.04.011","article-title":"Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development","volume":"149","author":"Reijns","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.berh.2017.12.002_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1084\/jem.20151464","article-title":"RNase H2 catalytic core Aicardi-Gouti\u00e8res syndrome\u2013related mutant invokes cGAS\u2013STING innate immune-sensing pathway in mice","volume":"213","author":"Pokatayev","year":"2016","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.berh.2017.12.002_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1469-8749.2010.03727.x","article-title":"Intracerebral large artery disease in Aicardi\u2013Gouti\u00e8res syndrome implicates SAMHD1 in vascular homeostasis","volume":"52","author":"Ramesh","year":"2010","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.berh.2017.12.002_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ajmg.a.33778","article-title":"Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus","volume":"155","author":"Ravenscroft","year":"2011","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.berh.2017.12.002_bib45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng.373","article-title":"Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.celrep.2013.07.037","article-title":"Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response","volume":"4","author":"Behrendt","year":"2013","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.berh.2017.12.002_bib47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ni.1680","article-title":"ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling","volume":"10","author":"Hartner","year":"2009","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.immuni.2013.12.014","article-title":"Autoimmune disorders associated with gain of function of the intracellular sensor MDA5","volume":"40","author":"Funabiki","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.berh.2017.12.002_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10875-015-0147-3","article-title":"Human disease phenotypes associated with mutations in TREX1","volume":"35","author":"Rice","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"issue":"10","key":"10.1016\/j.berh.2017.12.002_bib50","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ajmg.a.33620","article-title":"A\u00a0de novo p. Asp18Asn mutation in TREX1 in a patient with Aicardi\u2013Gouti\u00e8res syndrome","volume":"152","author":"Haaxma","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1086\/513443","article-title":"Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome","volume":"80","author":"Rice","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib52","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/521373","article-title":"Clinical and molecular phenotype of Aicardi-Goutieres syndrome","volume":"81","author":"Rice","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.berh.2017.12.002_bib53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.berh.2017.12.002_bib54","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","author":"Rodero","year":"2017","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10072-014-1944-9","article-title":"TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy","volume":"36","author":"DiFrancesco","year":"2015","journal-title":"Neurol Sci"},{"issue":"9","key":"10.1016\/j.berh.2017.12.002_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/ng2082","article-title":"C-terminal truncations in human 3\u2032-5\u2032 DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy","volume":"39","author":"Richards","year":"2007","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.berh.2017.12.002_bib57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10875-016-0252-y","article-title":"Spondyloenchondrodysplasia due to mutations in ACP5: a comprehensive survey","volume":"36","author":"Briggs","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajmg.a.31081","article-title":"Spondyloenchondrodysplasia with spasticity, cerebral calcifications, and immune dysregulation: clinical and radiographic delineation of a pleiotropic disorder","volume":"140","author":"Renella","year":"2006","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/ng.748","article-title":"Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature","volume":"43","author":"Briggs","year":"2011","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajhg.2014.12.014","article-title":"A\u00a0specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome","volume":"96","author":"Rutsch","year":"2015","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.berh.2017.12.002_bib61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajhg.2014.11.019","article-title":"Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome","volume":"96","author":"Jang","year":"2015","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.berh.2017.12.002_bib62","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.20151529","article-title":"Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome","volume":"213","author":"Meuwissen","year":"2016","journal-title":"J\u00a0Exp Med"},{"issue":"7532","key":"10.1016\/j.berh.2017.12.002_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature13801","article-title":"Human intracellular ISG15 prevents interferon-\u03b1\/\u03b2 over-amplification and auto-inflammation","volume":"517","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.berh.2017.12.002_bib64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2012.02.009","article-title":"SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome","volume":"90","author":"Fabre","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib65","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.berh.2017.12.002_bib66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694217301018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694217301018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:16:58Z","timestamp":1761499018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694217301018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1521694217301018"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2017.12.002","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic interferonopathies: An overview","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}